Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...
Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback